Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Viking Therapeutics (VKTX)
NASDAQ:VKTX
Viking Therapeutics (VKTX) Stock Price & Analysis
3,906 Followers
VKTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$8.28 - $99.41
Previous Close$57.18
Volume2.14M
Average Volume (3M)3.44M
Market Cap
$6.31B
Enterprise Value$5.34B
Total Cash (Recent Filing)$962.98M
Total Debt (Recent Filing)$1.18M
Price to Earnings (P/E)―
Beta1.86
Next Earnings
Jul 24, 2024EPS Estimate
-$0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.93
Shares Outstanding110,268,210
10 Day Avg. Volume3,457,472
30 Day Avg. Volume3,438,162
Standard Deviation0.37
R-Squared0.02
Alpha0.06
Financial Highlights & Ratios
Price to Book (P/B)6.23
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-237.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-342.00
Forecast
1Y Price Target
$112.63Price Target Upside89.68% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
Viking Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical UpdatesClinical updates for both subQ and oral VK2735 are seen as potentially providing additional differentiating features and optionality.
Market OpportunitiesThe NASH/MASH market is in the early stages of development but represents another potentially large market opportunity.
Pipeline And EfficacyVK2735 is a next generation GLP-1/GIP agonist in development for obesity that has demonstrated a favorable profile and has the added advantage of an oral, tablet formulation with a notably clean tolerability profile.
Bears Say
Comparative Data ChallengesCross trial comparisons remain challenging; Roche disclosed the Phase Ib data resulted in 18.8% pbo-adjusted weight loss over 24-weeks, which is encouraging, but lacking important details on dosing, safety/tolerability, and the kinetics on weight loss overtime.
Data Disclosure IssuesRoche's data disclosure does not present safety/tolerability data from the study, which is an important consideration for the class.
Partnership ConcernsViking is trading down ~10% vs. ~0.4% XBI which is attributed to overall investor concerns around timing and likelihood of partnerships for Viking in the large Obesity and NASH markets.
---
Ownership Overview
8.83% Insiders
26.95% Mutual Funds
12.89% Other Institutional Investors
51.32% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VKTX FAQ
What was Viking Therapeutics’s price range in the past 12 months?
Viking Therapeutics lowest stock price was $8.28 and its highest was $99.41 in the past 12 months.
What is Viking Therapeutics’s market cap?
Currently, no data Available
When is Viking Therapeutics’s upcoming earnings report date?
Viking Therapeutics’s upcoming earnings report date is Jul 24, 2024 which is 2 days ago.
How were Viking Therapeutics’s earnings last quarter?
Viking Therapeutics released its earnings results on Apr 24, 2024. The company reported -$0.26 earnings per share for the quarter, beating the consensus estimate of -$0.277 by $0.017.
Is Viking Therapeutics overvalued?
According to Wall Street analysts Viking Therapeutics’s price is currently Undervalued.
Does Viking Therapeutics pay dividends?
Viking Therapeutics does not currently pay dividends.
What is Viking Therapeutics’s EPS estimate?
Viking Therapeutics’s EPS estimate is -$0.26.
How many shares outstanding does Viking Therapeutics have?
Viking Therapeutics has 110,268,210 shares outstanding.
What happened to Viking Therapeutics’s price movement after its last earnings report?
Viking Therapeutics reported an EPS of -$0.26 in its last earnings report, beating expectations of -$0.277. Following the earnings report the stock price went up 5.824%.
Which hedge fund is a major shareholder of Viking Therapeutics?
Among the largest hedge funds holding Viking Therapeutics’s share is Viking Global Investors LP. It holds Viking Therapeutics’s shares valued at 90M.
---
Viking Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$112.63 (89.68% Upside)
$112.63 (89.68% Upside)
Blogger Sentiment
Bullish
VKTX Sentiment 97%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 3.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.8%
Last 30 Days ▲ 2.0%
Last 30 Days ▲ 2.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
271.53%
12-Months-Change
Fundamentals
Return on Equity
-17.55%
Trailing 12-Months
Asset Growth
541.19%
Trailing 12-Months
Company Description
Viking Therapeutics
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for patients suffering from metabolic and endocrine disorders. The company's clinical program VK5211, treats patients recovering from non-elective hip fracture surgery. It also specializes in development of VK2809 and VK0214. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.
---
VKTX Earnings Call
Q1 2024
0:00 / 0:00
---
VKTX Stock 12 Month Forecast
Average Price Target
$112.63
▲(89.68% Upside)
Technical Analysis
Best Analysts Covering VKTX
1 Year
1 Year Success Rate
13/16 ratings generated profit
1 Year Average Return
+210.25%
reiterated a buy rating last month
Copying Naz Rahman's trades and holding each position for 1 Year would result in 81.25% of your transactions generating a profit, with an average return of +210.25% per trade.
---